MEDICAL PROPERTIES TRUST INC
MPWDrugs in Pipeline
13
Phase 3 Programs
8
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Relaxin
Heart Failure, Congestive
Sevre-Long™
Opiate Dependent
Midazolam
Sedation
Active Theramine and Active Naproxen
Low Back Pain
GDC 268 Lotion
Acne Vulgaris
IVACFLU-S
Influenza, Human
Isoflurane
Sedation
Ibuprofen and Aprepitant
Primary Dysmenorrhea
Tavokinogene Telseplasmid (tavo)
Melanoma
Oxytocin 100 i.u.
Vaginal Atrophy
Glyceryl trinitrate
Erectile Dysfunction
Aramchol
Non-Alcoholic Fatty Liver Disease
Oxytocin
Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Relaxin | Phase 3 | Heart Failure, Congestive | - | - |
Sevre-Long™ | Phase 3 | Opiate Dependent | - | - |
Midazolam | Phase 3 | Sedation | - | - |
Active Theramine and Active Naproxen | Phase 3 | Low Back Pain | - | - |
GDC 268 Lotion | Phase 3 | Acne Vulgaris | - | - |
IVACFLU-S | Phase 3 | Influenza, Human | - | - |
Isoflurane | Phase 3 | Sedation | - | - |
Ibuprofen and Aprepitant | Phase 3 | Primary Dysmenorrhea | - | - |
Tavokinogene Telseplasmid (tavo) | Phase 2 | Melanoma | - | - |
Oxytocin 100 i.u. | Phase 2 | Vaginal Atrophy | - | - |
Glyceryl trinitrate | Phase 2 | Erectile Dysfunction | - | - |
Aramchol | Phase 2 | Non-Alcoholic Fatty Liver Disease | - | - |
Oxytocin | Phase 2 | Atrophy | - | - |